Assurance Infusion Recalls Hydromorphone Injection Due to Sterility Concerns
Assurance Infusion is recalling specific lots of Hydromorphone 6mg/mL injection due to a lack of sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a lack of sterility assurance in an injectable drug, which poses a significant risk of serious injury or infection.
Plain-English summary
Assurance Infusion is recalling Hydromorphone 6mg/mL Injection in 20 mL syringes. The recall is being conducted because of a lack of sterility assurance for the product.
The affected product is identified by Lot 12132019@9 with an expiration date of 12/22/2019. The product was distributed nationwide within the United States.
Consumers and healthcare providers should stop using the affected product and contact Assurance Infusion at (713) 533-8800 for further instructions.
The recalled product
- Product
- HYDROMORPHONE 6MG/ML INJ in 20 mL syringe Assurance Infusion (713) 533-8800
- Manufacturer
- Assurance Infusion
- Category
- Drug — Injectable
- Hazard
- Affected units
- 1
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 12132019@9 Exp. 12/22/2019
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 118 recalled by Assurance Infusion under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 118 products in this recall →Related recalls
Same manufacturer · Assurance Infusion
See all →- SevereAssurance Infusion Recalls Buprenorphine and Hydromorphone Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Hydromorphone Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Fentanyl Syringes Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Morphine Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Buprenorphine and Morphine Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
Same hazard · lack of sterility
See all →- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereWalgreens Lubricant Eye Drops Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
Similar recalls
- HighHydromorphone Syringe Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighHYDROmorphone Injectable Syringes Recalled Over Sterility Assurance Issues
FDA (Drugs) · 2023-10-11
- HighHYDROmorphone Injectable Syringes Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2023-08-09
- HighHydromorphone Injection Syringes Recalled for Sterility Validation Deficiency
FDA (Drugs) · 2023-08-09
- HighHYDROmorphone HCl 6 mg Injectable Syringes Recalled Due to Sterility Assurance Issues
FDA (Drugs) · 2024-04-03
- HighFDA Recalls HYDROmorphone Syringes for Sterility Assurance Issue
FDA (Drugs) · 2023-10-11